Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

CD40 is a cell-surface molecule that critically regulates immune responses. CP-870,893 is a fully human, CD40-specific agonist monoclonal antibody (mAb) exerting clinical antineoplastic activity. Here, the safety of CP-870,893 combined with carboplatin and paclitaxel was assessed in a Phase I study....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Vonderheide, Robert H., Burg, Jennifer M., Mick, Rosemarie, Trosko, Jennifer A., Li, Dongguang, Shaik, M. Naveed, Tolcher, Anthony W., Hamid, Omid
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2013
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3583942/
https://ncbi.nlm.nih.gov/pubmed/23483678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.23033
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items